Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2020 / N 2

Лечение нейрогенного гиперактивного мочевого пузыря ботулиническим токсином
Р.В. Салюков, Ю.Р. Салюкова

References

1. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World Journal of Urology 2003 May;20(6):327-36.
2. Mazo EB, Krivoborodov GG. Overactive bladder. Moscow: Veche; 2003. 160 p. (In Russian).
3. Marinkovic SP, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. The Journal of Urology 2001 Feb;165(2):359-70.
4. Rotar M, Blagus R, Jeromel M, Skrbec M, Tršinar B, Vodušek DB. Stroke patients who regain urinary continence in the first week after acute first-ever stroke have better prognosis than patients with persistent lower urinary tract dysfunction. Neurourology and Urodynamics 2011 Sep;30(7):1315-8.
5. Grant RL, Drennan VM, Rait G, Petersen I, Iliffe S. First diagnosis and management of incontinence in older people with and without dementia in primary care: a cohort study using The Health Improvement Network Primary Care database. PLoS Medicine 2013 Aug;10(8): e1001505.
6. Ragab MM, Mohammed ES. Idiopathic Parkinson’s disease patients at the urologic clinic. Neurourology and Urodynamics 2011 Sep;30(7):1258-61.
7. Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H; Parkinson’s Disease Subcomittee; The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourology and Urodynamics 2016 Jun;35(5):551-63.
8. Marciniak C, O’Shea SA, Lee J, Jesselson M, Dudas-Sheehan D, Beltran E, Gaebler-Spira D. Urinary incontinence in adults with cerebral palsy: prevalence, type, and effects on participation. PM & R 2014 Feb;6(2):110-20; quiz 120.
9. Kulaklı F, Koklu K, Ersoz M, Ozel S. Relationship between urinary dysfunction and clinical factors in patients with traumatic brain injury. Brain Injury 2014;28(3):323-7.
10. Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology 2000 Apr;55(4):490-4.
11. Yuan Z, Tang Z, He C, Tang W. Diabetic cystopathy: a review. Journal of Diabetes 2015 Jul;7(4):442-7.
12. de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B; GENULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis (Houndmills, Basingstoke, England) 2007 Aug;13(7):915-28.
13. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Urology 2003 Jan;61(1):37-49.
14. Pushkar DYu, Kasyan GR. Functional urology and urodynamics: monograph. Moscow: Geotar-Media; 2013. 375 p. (In Russian).
15. European Association of Urology. EAU Guidelines on neuro-urology. 2017. Available from: http://uroweb.org/wp-content/uploads/15-Neuro-Urology_2017_web.pdf Accessed 2020 May 25.
16. Nardulli R, Losavio E, Ranieri M, Fiore P, Megna G, Bellomo RG, Cristella G, Megna M. Combined antimuscarinics for treatment of neurogenic overactive bladder. International Journal of Immunopathology and Pharmacology 2012 Jan-Mar;25(1 Suppl):35S-41S.
17. Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. European Urology 2012 Nov;62(5):816-30.
18. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourology and Urodynamics 2006;25(5):441-5.
19. Korshunova ES, Korshunov MN, Darenkov SP. Neurogenic and idiopathic overactive bladder: stumbling blocks. Consilium Medicum 2019;21(7):53-7 (In Russian).
20. Isik AT, Celik T, Bozoglu E, Doruk H. Trospium and cognition in patients with late onset Alzheimer disease. The Journal of Nutrition, Health & Aging 2009 Oct;13(8):672-6.
21. Welk B, Hickling D, McKibbon M, Radomski S, Ethans K. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourology and Urodynamics 2018 Nov;37(8):2810-17.
22. Barendrecht MM, Oelke M, Laguna MP, Michel MC. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU International 2007 Apr;99(4):749-52.
23. McClurg D, Ashe RG, Lowe-Strong AS. Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis – a double blind, placebo controlled, randomised clinical trial. Neurourology and Urodynamics 2008;27(3):231-7.
24. Gross T, Schneider MP, Bachmann LM, Blok BF, Groen J, Hoen LA, Castro-Diaz D, Padilla Fernández B, Del Popolo G, Musco S, Hamid R, Ecclestone H, Karsenty G, Phé V, Pannek J, Kessler TM. Transcutaneous electrical nerve stimulation for treating neurogenic lower urinary tract dysfunction: a systematic review. European Urology 2016 Jun;69(6):1102-11.
25. Tibaek S, Gard G, Dehlendorff C, Iversen HK, Biering-Soerensen F, Jensen R. Is pelvic floor muscle training effective for men with post-stroke lower urinary tract symptoms? A single-blinded randomized, controlled trial. American Journal of Men’s Health 2017 Sep;11(5):1460-71.
26. Shin DC, Shin SH, Lee MM, Lee KJ, Song CH. Pelvic floor muscle training for urinary incontinence in female stroke patients: a randomized, controlled and blinded trial. Clinical Rehabilitation 2016 Mar;30(3):259-67.
27. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. European Urology 2011 Oct;60(4):742-50.
28. Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, Novara G, Chapple C. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. European Urology 2014 May;65(5):981-90.
29. Apostolidis A, Rahnama’i MS, Fry C, Dmochowski R, Sahai A. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014. Neurourology and Urodynamics 2016 Feb;35(2):293-8.
30. Weil EH, Ruiz-Cerdá JL, Eerdmans PH, Janknegt RA, Bemelmans BL, van Kerrebroeck PE. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. European Urology 2000 Feb;37(2):161-71.
31. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JPFA, Lycklama @á Nijholt AAB, Siegel S, Jonas U, Fowler CJ, Fall M, Gajewski JB, Hassouna MM, Cappellano F, Elhilali MM, Milam DF, Das AK, Dijkema HE, van den Hombergh U. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. The Journal of Urology 2007 Nov;178(5):2029-34.
32. Krebs J, Bartel P, Pannek J. Functional outcome of supratrigonal cystectomy and augmentation ileocystoplasty in adult patients with refractory neurogenic lower urinary tract dysfunction. Neurourology and Urodynamics 2016 Feb;35(2):260-6.
33. Cody JD, Nabi G, Dublin N, McClinton S, Neal DE, Pickard R, Yong SM. Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. The Cochrane Database of Systematic Reviews 2012 Feb;(2):CD003306.
34. Salyukov RV, Kolmakov AS, Martov AG. Onabolotulinumtoxin A in treating detrusor hyperactivity in patients with spinal cord injury: literature review. Consilium Medicum 2019;21(7):58-63 (In Russian).
35. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. European Urology 2003 Aug;44(2):165-74.
36. European Association of Urology. Guidelines on urological infections. 2015. Available from: https://uroweb.org/wp-content/uploads/19-Urological-infections_LR2.pdf Accessed 2020 May 25.
37. Mouttalib S, Khan S, Castel-Lacanal E, Guillotreau J, De Boissezon X, Malavaud B, Marqui F, Rischmann P, Gamé X. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU International 2010;106:1677-80.
38. Kezina LP, Salyukov RV, Tishchenko GE. Catheters for periodic bladder catheterization as a technical tool for rehabilitation of patients with neurogenic lower urinary tract dysfunction: issues of organization of disabled providing. Physical and Rehabilitation Medicine. Medical Rehabilitation 2019;4(4):77-81 (In Russian).
39. Lopatkin NA, Salyukov RV, Martov AG, Chepurov DA, Ibragimov AR. Botulinum toxin in treatment of functional urinary disorders. In: Selected lectures on urology. Lopatkin NA, Martova AG, editors. Moscow: MIA; 2008: 13-25 (In Russian).
40. Huang M, Chen H, Jiang C, Xie K, Tang P, Ou R, Zeng J, Liu Q, Li Q, Huang J, Huang T, Zeng W. Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia. Journal of Rehabilitation Medicine 2016 Oct;48(8):683-7.
41. Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C. Phase 3 efficacy and tolerability study of onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. The Journal of Urology 2012 Jun;187(6):2131-9.
42. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. The Journal of Urology 1996 Mar;155(3):1023-9.
43. Koschorke M, Leitner L, Sadri H, Knüpfer SC, Mehnert U, Kessler TM. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment? BJU International 2017 Dec;120(6):848-54.
44. Leitner L, Guggenbühl-Roy S, Knüpfer SC, Walter M, Schneider MP, Tornic J, Sammer U, Mehnert U, Kessler TM. More than 15 years of experience with intradetrusor onabotulinumtoxinA injections for treating refractory neurogenic detrusor overactivity: lessons to be learned. European Urology 2016 Sep;70(3):522-8.
45. Joussain C, Popoff M, Phé V, Even A, Bosset PO, Pottier S, Falcou L, Levy J, Vaugier I, Chartier Kastler E, Schurch B, Denys P. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Neurourology and Urodynamics 2018 Feb;37(2):799-806.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]